New statistical tool improves the ability to find genetic variants that cause disease

A new statistical tool developed by researchers at the University of Chicago improves the ability to find genetic variants that cause disease. The tool, described in a new paper published January 26, 2024, in Nature Genetics, combines data from genome wide association studies (GWAS) and predictions of genetic expression to limit the number of false positives and more accurately identify causal genes and variants for a disease.

GWAS is a commonly used approach to try to identify genes associated with a range of human traits, including most common diseases. Researchers compare genome sequences of a large group of people with a specific disease, for example, with another set of sequences from healthy individuals. The differences identified in the disease group could point to genetic variants that increase risk for that disease and warrant further study.

Most human diseases are not caused by a single genetic variation, however. Instead, they are the result of a complex interaction of multiple genes, environmental factors, and host of other variables. As a result, GWAS often identifies many variants across many regions in the genome that are associated with a disease. The limitation of GWAS, however, is that it only identifies association, not causality. In a typical genomic region, many variants are highly correlated with each other, due to a phenomenon called linkage disequilibrium. This is because DNA is passed from one generation to next in entire blocks, not individual genes, so variants nearby each other tend to be correlated.

You may have many genetic variants in a block that are all correlated with disease risk, but you don't know which one is actually the causal variant. That's the fundamental challenge of GWAS, that is, how we go from association to causality."

Xin He, PhD, Associate Professor of Human Genetics, and senior author of the new study

To make the problem even harder, most of the genetic variants are located in non-coding genomes, making their effects difficult to interpret. A common strategy to address these challenges is using gene expression levels. Expression quantitative trait loci, or eQTLs, are genetic variants associated with gene expression.

The rationale of using eQTL data is that if a variant associated with a disease is an eQTL of some gene X, then X is possibly the link between the variant and the disease. The problem with this reasoning, however, is that nearby variants and eQTLs of other genes can be correlated with the eQTL of the gene X while affecting the disease directly, leading to a false positive. Many methods have been developed to nominate risk genes from GWAS using eQTL data, but they all suffer from this fundamental problem of confounding by nearby associations. In fact, existing methods can generate false positive genes more than 50% of the time.

In the new study, Prof. He and Matthew Stephens, PhD, the Ralph W. Gerard Professor and Chair of the Departments of Statistics and Professor of Human Genetics, developed a new method called causal-Transcriptome-wide Association studies, or cTWAS, that uses advanced statistical techniques to reduce false positive rates. Instead of focusing on just one gene at a time, the new cTWAS model accounts for multiple genes and variants. Using a Bayesian multiple regression model, it can weed out confounding genes and variants.

"If you look at one at a time, you'll have false positives, but if you look at all the nearby genes and variants together, you are much more likely to find the causal gene," He said.

The paper demonstrates the utility of this new technique by studying genetics of LDL cholesterol levels. As one example, existing eQTL methods nominated a gene involved in DNA repair, but the new cTWAS approach pointed at a different variant in the target gene of statin, a common drug used to treat high cholesterol. In total, cTWAS identified 35 putative causal genes of LDL, more than half of which have not been previously reported. These results point to new biological pathways and potential treatment targets for LDL.

The cTWAS software is now available to download from He's lab website. He hopes to continue working on it to extend its capabilities to incorporate other types of 'omics data, such as splicing and epigenetics, as well as using eQTLs from multiple tissue types.

"The software will allow people to do analyses that connect genetic variations to phenotypes. That's really the key challenge facing the entire field," He said. "We now have a much better tool to make those connections."

Source:
Journal reference:

Zhao, S., et al. (2024). Adjusting for genetic confounders in transcriptome-wide association studies improves discovery of risk genes of complex traits. Nature Genetics. doi.org/10.1038/s41588-023-01648-9.

Comments

  1. Laurie Belvin Laurie Belvin United States says:

    I have an ultra-rare cancer, Erdheim-Chester Disease.  As yet, the mutations that cause my cancer have not been found.  I am taking a targeted chemotherapy that seems to keep it from replicating itself, but a cure would require better understanding my genetics to start. Please consider a clinical trial or research for those of us with this deadly cancer.  I am Laurie in Florida with. ECD.  Dr.Diamond at Sloan Kettering would be your best contact for info.

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Cervix organ chips pave the way for next-generation studies on host-microbiome interactions